Abstract: One aspect of the present application relates to a method of decomposing a polymeric reactant. This method comprises reacting the polymeric reactant in an oxygen containing ionized gas plasma to decompose the polymeric reactant and produce oxygen-functionalized products. The reacting is carried out at a temperature of 20 to 450° C. Another aspect of the present application relates to a method of removing carbon dioxide and/or carbon monoxide from a gas mixture. This method comprises providing a gas mixture comprising carbon dioxide and/or carbon monoxide. The gas mixture is contacted with a polymeric reactant in an ionized gas plasma to remove carbon dioxide and/or carbon monoxide from the gas mixture and produce oxygen-functionalized products.

Abstract: Provided is a controller, an air conditioner, and a high-pressure protection circuit. The controller includes a first rectifier unit, a power conversion unit, a high pressure switch (HPS) wiring terminal, a low-voltage control unit, and a high-voltage operating unit. An input end of the first rectifier unit is capable of being electrically connected to an input power supply. An output end of the first rectifier unit is electrically connected to an input end of the power conversion unit. An output end of the power conversion unit is electrically connected to a power supply end of the low-voltage control unit. The HPS wiring terminal is connected to the front end of the power supply end of the low-voltage control. The controller has a function of high-pressure protection.

Abstract: A data processing method in a virtual scene, a device, a storage medium, and a program product are provided. The method includes receiving an operation instruction, the operation instruction being an instruction triggered by a route drawing operation on a second minimap that is displayed on a second terminal; generating path information of a target virtual object in a virtual scene based on the operation instruction; and transmitting the path information to a first terminal, the first terminal displaying a path trajectory corresponding to the path information on a first minimap that is displayed by the first terminal.

Abstract: A multicomponent crystal (or co-crystal) comprising a first active pharmaceutical ingredient and a second active pharmaceutical ingredient. The multicomponent crystal is formed/sustained by non-covalent interactions between the nitrogen-containing heterocycle alpha-substituted with an amino group of the first active pharmaceutical ingredient and a carboxylic acid group of the second active pharmaceutical ingredient, suitably as well as other further non-covalent interactions with other H-bond forming groups. The multicomponent crystal may provide an improved multidrug dosage form comprising lamotrigine and valproic acid as the first and second active pharmaceutical ingredients, respectively. A pharmaceutical composition comprising a therapeutically effective amount of the multicomponent crystal and a pharmaceutically acceptable excipient, and a method of forming the multicomponent crystal, are also provided.

Abstract: Disclosed herein are compositions, systems, and methods of using dual-layer hollow fiber membranes. The compositions and systems of the disclosure can be used to desalinate water from an underground formation. The compositions and systems of the disclosure can be further used to capture carbon dioxide from a gaseous sample.

Abstract: The present invention provides an application of lncRNAs ENST00000607393 siRNA in preparing a preparation for treating glaucoma. The present invention clarifies the correlation between the expression level of ENST00000607393 and the calcification of human primary trabecular meshwork cells. The expression level of ENST00000607393 in human primary trabecular meshwork cells is firstly down-regulated to 46.21% of a control group by siRNA interference. Under the condition of intervening with the cells by a 500 ?mol/L hydrogen peroxide solution for 48 hours, it is observed that compared with the control group, the down-regulation of ENST00000607393 expression can significantly decrease the ALP activity in human primary trabecular meshwork cells, and thus significantly decrease the calcification level of human primary trabecular meshwork cells to play a role of treating or preventing glaucoma.

Abstract: The present invention provides two molecular markers, lncRNAs ENST00000607393 and lncRNAs ENST00000508241, diagnostic kits and applications for glaucoma diagnosis. Compared with people in a control group, the expressions of lncRNAs: ENST00000607393 are all up-regulated in aqueous humors, irises and serums of patients with glaucoma, and the expression of lncRNAs: ENST00000508241 is up-regulated in aqueous humors of patients with glaucoma. It indicates that ENST00000607393 and ENST00000508241 are highly expressed lncRNAs in glaucoma and are biomarkers that contribute to the diagnosis of glaucoma. The present invention provides a strong molecular biology basis for the diagnosis of glaucoma, and has far-reaching clinical significance and generalization performance.

Abstract: The present invention provides an application of lncRNAs ENST00000607393 siRNA in preparing a preparation for treating glaucoma. The present invention clarifies the correlation between the expression level of ENST00000607393 and the calcification of human primary trabecular meshwork cells. The expression level of ENST00000607393 in human primary trabecular meshwork cells is firstly down-regulated to 46.21% of a control group by siRNA interference. Under the condition of intervening with the cells by a 500 ?mol/L hydrogen peroxide solution for 48 hours, it is observed that compared with the control group, the down-regulation of ENST00000607393 expression can significantly decrease the ALP activity in human primary trabecular meshwork cells, and thus significantly decrease the calcification level of human primary trabecular meshwork cells to play a role of treating or preventing glaucoma.

Abstract: The present invention discloses three molecular markers kits and applications for glaucoma diagnosis. The expressions of lncRNAs: T342877, lncRNAs: NR_026887, and lncRNAs: TCONS_00025577 are up-regulated in aqueous humors of patients with glaucoma compared with people in a control group. It indicates that lncRNAs: T342877, lncRNAs: NR_026887, and lncRNAs: TCONS_00025577 are highly expressed lncRNAs in glaucoma and are biomarkers that contribute to the diagnosis of glaucoma. The present invention provides a strong molecular biology basis for the diagnosis of glaucoma, and has far-reaching clinical significance and generalization performance.

Abstract: The present invention discloses two molecular markers, kits and applications for glaucoma diagnosis. Compared with people in a control group, the expressions of lncRNAs: T267384 are all up-regulated in aqueous humors and serums of patients with glaucoma, and the expression of lncRNAs: ENST00000564363 is up-regulated in aqueous humors of patients with glaucoma. It indicates that T267384 and ENST00000564363 are highly expressed lncRNAs in glaucoma and are biomarkers that contribute to the diagnosis of glaucoma. The present invention provides a strong molecular biology basis for the diagnosis of glaucoma, and has far-reaching clinical significance and generalization performance.

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.

Abstract: The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.

Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Abstract: The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.

Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Abstract: Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid.

Abstract: The invention relates to a pharmaceutical composition containing pimobendan as an active ingredient. The invention also relates to a crystalline form of pimobendan, as well as to a combination of said crystalline form with at least one other therapeutically active ingredient. Moreover, the invention relates to uses of said crystalline form, as well as to a pharmaceutical composition containing it. Finally, the invention relates to a process for preparing a crystalline form of pimobendan.

Abstract: The invention provides an improved, highly efficient method for preparing 5-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole, and its salts, in particular its pharmaceutically acceptable salts.

Abstract: The present invention relates to a process for preparing and purifying crystalline quetiapine hemifumarate, which comprises preparing crystalline quetiapine hemifumarate via a crystalline salt, which is not a salt of fumaric acid.